一分钟看懂
这是一项关于神经内分泌癌的III 期研究，登记的药物或干预包括Obrixtamig；Carboplatin；Etoposide；Ventana DLL3 RxDx assay，当前状态为招募中。登记地点显示中国北京、长春、长沙、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Obrixtamig；Carboplatin；Etoposide；Ventana DLL3 RxDx assay · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- Beijing GoBroad Hospital · 北京
- The First Hospital of Jilin University · 长春
- Xiangya Hospital, Central South University · 长沙
- Hunan Province Tumor Hospital · 长沙
- Sichuan Cancer Hospital · 成都
- West China Hospital, Sichuan University · 成都
- Chongqing University Affiliated Cancer Hospital · 重庆
- Fujian Cancer Hospital · 福州
- The First Affiliated Hospital,Sun Yat-sen University · 广州
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Qilu Hospital, Shangdong University · 济南
- Shandong Cancer Hospital · 济南
- Linyi Cancer Hospital · 临沂
- The First Affiliated Hospital of Henan University of Science and Technology · 洛阳
- The Affiliated Cancer Hospital, Guangxi Medical University · 南宁
- Shanghai General Hospital · 上海
- Hubei Cancer Hospital · 武汉
- First Affiliated Hospital of Xi'an JiaoTong University · 西安
- First Affiliated Hospital of Xiamen University · 厦门
- The First Affiliated Hospital of Zhengzhou University · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Patients with poorly differentiated unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinoma (epNEC) with Ki-67 \>20% or mitotic rate mitotic rate with number of mitoses \>20 per 2 mm2, regardless of primary site (including site of unknown origin)
- 2. Patients with tumours with mixed histologies are eligible only if neuroendocrine carcinoma component is predominant and represents more than 70% of the overall tumour tissue
- 3. No prior systemic treatment for unresectable locally advanced or metastatic epNEC (except for the completed one cycle of standard platinum + etoposide). Prior peri-operative chemotherapy or -radiation for curative intention is allowed if at least 6 months have elapsed between completion of this therapy and diagnosis of unresectable locally advanced or metastatic disease
- 4. Patients who have finished one cycle of standard platinum + etoposide regimen as first-line treatment (Cycle 0: etoposide with carboplatin or cisplatin, administered at a minimum dose of cisplatin 75 mg/m2 or carboplatin area under the curve (AUC) 5 and etoposide 80 mg/m2) prior to randomisation
- 5. Patients must comply with criteria for receiving further chemotherapy treatment as first-line standard of care (SoC) treatment within 28 days after the start of the initial chemotherapy (Cycle 0)
- 6. Adequate archival Formalin-Fixed Paraffin-Embedded (FFPE) tumour tissue, as specified in the Laboratory Manual, must be available for central laboratory analysis of Delta-like ligand 3 (DLL3) expression status. Tumours must be positive (as defined in the diagnostic study protocol) for DLL3 expression status assessed by investigational VENTANA DLL3 (SP347) RxDx Assay
- 7. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- 8. Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the informed consent form (ICF) Further inclusion criteria apply.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07544654；登记信息更新于 2026-09-29；本站同步于 2026-10-08。